Lapatinib and Capecitabine

DRUG2 trials

Sponsors

GlaxoSmithKline, Georgetown University

Conditions

Neoplasms, Gastrointestinal TractPancreas Cancer

Phase 2

Study For Patients With Untreated Gastric Cancer Who Will Receive Capecitabine And Lapatinib

CompletedNCT00526669

GlaxoSmithKlineNeoplasms, Gastrointestinal Tract

Start: 2008-03-31End: 2015-01-31Updated: 2016-01-29

Lapatinib and Capecitabine for Second Line Treatment of Pancreas Cancer

TerminatedNCT00881621

Georgetown UniversityPancreas Cancer

Start: 2009-08-31End: 2013-06-30Updated: 2025-03-03

Related Papers

A Phase II Biomarker-Embedded Study of Lapatinib plus Capecitabine as First-line Therapy in Patients with Advanced or Metastatic Gastric Cancer

Molecular Cancer Therapeutics2016-06-2110 citations